What is NAGE's pharmaceuticals segment — R&D?

NAGE (NAGE) reported pharmaceuticals segment — R&D of $468K in Q1 2026.

How has NAGE's pharmaceuticals segment — R&D changed year-over-year?

NAGE's pharmaceuticals segment — R&D increased by 27.2% year-over-year, from $368K to $468K.

What does pharmaceuticals segment — R&D mean?

Represents the investment in scientific research, clinical trials, and product development for new or existing pharmaceutical therapies. This is a vital indicator of the segment's future innovation pipeline and long-term growth potential. High levels of expenditure reflect a strategic focus on expanding the product portfolio.

NAGE NAGE Pharmaceuticals segment — R&D

Other segment segments

Consumer Products segment

$733K+13.6%

Ingredients segment

$280K+14.3%

Analytical Reference Standards and Services segment

$0—

Similar metrics at other companies

BAXPharmaceuticals — Research and development expenses

$22M-15.4%

BLCOPharmaceuticals — R&D

$22M+144%

ABTEstablished Pharmaceuticals — R&D

$41M-2.4%

VRTXPharmaceuticals — Research expenses

$205M-0.5%

LXRXReportable Segment — R&D

$11.39M-16.3%

OPKPharmaceutical — Research And Development Expense

$28.75M-4.9%

Other financials

Income statement

See full

Revenue$31.5M+3.3%

Gross profit$20.0M+3.3%

Operating income$1.6M-67.0%

Net income$6.3M+24.8%

EPS (diluted)$0.07+16.7%

Balance sheet

See full

Cash & equivalents$66.5M+19.7%

Total debt$2.6M-26.9%

Total equity$82.3M+48.8%

Total assets$114.3M+40.6%

Cash flow

See full

Operating cash flow-$1.2M-115%

Valuation

See full

Market cap$254.07M-74.9%

Enterprise value$190.09M-79.7%

P/E13.6×-43.5×

P/S2×-6.8×

Profitability

See full

Gross margin64.3%+1.8pp

Operating margin10%-2.2pp

Net margin14.3%+1.2pp

FCF margin-70.4%—

Returns & leverage

See full

Return on equity27.1%-6.4pp

Debt / equity0×0.0×

Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's pharmaceuticals segment — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NAGE's pharmaceuticals segment — R&D?: NAGE (NAGE) reported pharmaceuticals segment — R&D of $468K in Q1 2026.
How has NAGE's pharmaceuticals segment — R&D changed year-over-year?: NAGE's pharmaceuticals segment — R&D increased by 27.2% year-over-year, from $368K to $468K.
What does pharmaceuticals segment — R&D mean?: Represents the investment in scientific research, clinical trials, and product development for new or existing pharmaceutical therapies. This is a vital indicator of the segment's future innovation pipeline and long-term growth potential. High levels of expenditure reflect a strategic focus on expanding the product portfolio.